Potential Shortages of Hydroxychloroquine for Patients with Lupus During the Coronavirus Disease 2019 Pandemic

The coronavirus disease 2019 (COVID-19) pandemic has created a global public health crisis and severe economic disruption.There are currently no effective therapies to prevent, treat, or cure COVID-19.To meet this need, the scientific community has mobilized to develop vaccines and drugs to prevent and treat COVID-19.Trials are underway to assess the effectiveness of existing drugs that hold promise in treating COVID-19.While the results of these trials are eagerly awaited, the US Food and Drug Administration recently authorized use of chloroquine and hydroxychloroquine for emergency treatment of COVID-19.In the US, chloroquine is used predominantly to treat infectious diseases, such as malaria.Its less-toxic metabolite, hydroxychloroquine, is prescribed for lupus, rheumatoid arthritis, and other autoimmune diseases.Indeed, hydroxychloroquine has long been a mainstay of lupus treatment, and it is the only drug shown to prevent progression to serious end-organ damage.Lupus is a complex autoimmune disease that predominantly affects young women. 1 The prevalence of lupus is higher and the severity greater among individuals from lower socioeconomic strata, African Americans, Hispanic Americans, and Asian Americans.Clinical features range from mild joint and skin involvement to life-threatening renal, hematologic, and/or central nervous system disease.Half of patients with lupus develop nephritis, the most common cause of morbidity and mortality.Patients with lupus who are impoverished and/or members of racial/ethnic minorities experience worse outcomes and increased mortality.1 Hydroxychloroquine is recommended for all patients with lupus, especially those with no contraindication such as pregnancy.It relieves constitutional, musculoskeletal, and mucocutaneous manifestations and decreases thrombotic events, organ damage, and mortality.Hydroxychloroquine helps maintain disease remission and prevent flares.Among patients with lupus that is not organ threatening, 80% achieve remission with hydroxychloroquine and may sustain it with this therapy for long periods. 2 Although there is no rigorous scientific evidence supporting the use of hydroxychloroquine in COVID-19 as of early April 2020, consumers are stockpiling the drug not only for treatment but also prophylaxis prompted by media reports of possible efficacy.A rationale for hydroxychloroquine use in COVID-19 is based on in vitro studies showing that chloroquine inhibits virus replication.3 Because hydroxychloroquine and chloroquine may have in vivo antiviral and anti-inflammatory effects, they offer a potential means to mitigate COVID-19.A recent small (n = 36), open-label nonrandomized trial in France suggested that therapy with hydroxychloroquine and azithromycin decreased viral load and replication, 4 garnering significant media attention.However, randomized clinical trials are required to assess the efficacy and safety of hydroxychloroquine as prophylaxis or treatment for COVID-19.The FDA has authorized its use for treatment of patients hospitalized with COVID-19 but not for prophylaxis.President Trump has touted hydroxychloroquine therapy, despite very limited evidence of efficacy.5,6 Since being prominently featured in the press and on social media as a potential COVID-19 therapy, demand for hydroxychloroquine has exploded and a shortage has ensued.Some physicians are prescribing it for prophylaxis as well as outpatient treatment of COVID-19, often along with azithromycin.Some health care workers are taking it as prophylaxis without any evidence to support this use.